Sibapriya Chaudhuri, Scott Thomas, Luika Timmerman, Pamela Munster
{"title":"Deciphering the role of homologous recombination deficiency mutations in the response to immune checkpoint inhibitors and PARP inhibitors","authors":"Sibapriya Chaudhuri, Scott Thomas, Luika Timmerman, Pamela Munster","doi":"10.53876/001c.90569","DOIUrl":"https://doi.org/10.53876/001c.90569","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"75 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138596163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lee D Cranmer, Eric Q. Konnick, Kevin Tatunay, Colin C Pritchard, Marianne E Dubard-Gault
{"title":"Combined germline and mosaic SDHA mutation is associated with a multicancer syndrome including neuroblastoma, renal cancer, and multifocal gastrointestinal tumor","authors":"Lee D Cranmer, Eric Q. Konnick, Kevin Tatunay, Colin C Pritchard, Marianne E Dubard-Gault","doi":"10.53876/001c.90547","DOIUrl":"https://doi.org/10.53876/001c.90547","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"64 32","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138594905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily C Liang, Aya Albittar, Jennifer J Huang, A. Hirayama, Erik L. Kimble, A. Portuguese, A. Chapuis, M. Shadman, Brian Till, Ryan D Cassaday, Filippo Milano, H. Kiem, Stanley R Riddell, C. Turtle, D. G. Maloney, J. Gauthier
{"title":"Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up","authors":"Emily C Liang, Aya Albittar, Jennifer J Huang, A. Hirayama, Erik L. Kimble, A. Portuguese, A. Chapuis, M. Shadman, Brian Till, Ryan D Cassaday, Filippo Milano, H. Kiem, Stanley R Riddell, C. Turtle, D. G. Maloney, J. Gauthier","doi":"10.53876/001c.90575","DOIUrl":"https://doi.org/10.53876/001c.90575","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"57 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138595264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Leyfman, Muskan Joshi, G. P. Menon, Chandler Park
{"title":"Mesenchymal Stem Cells as a Promising Cellular Anti-COVID-19 Therapy for Diffuse Large B Cell Lymphoma Patients affected by Severe SARS-CoV-2","authors":"Yan Leyfman, Muskan Joshi, G. P. Menon, Chandler Park","doi":"10.53876/001c.90843","DOIUrl":"https://doi.org/10.53876/001c.90843","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"23 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138598142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malak Alharbi, Archit Patel, Arya Mariam Roy, Kristopher Attwood, Chi-Chen Hong, Song Yao, T. Khoury, Amy Early, Tracey O’Connor, E. Levine, Shipra Gandhi
{"title":"Real-world Analysis of Efficacy and Adverse Events for Advanced Triple Negative Breast Cancer (TNBC) treated with Immune Checkpoint Inhibitors (ICI): A Single Center Experience","authors":"Malak Alharbi, Archit Patel, Arya Mariam Roy, Kristopher Attwood, Chi-Chen Hong, Song Yao, T. Khoury, Amy Early, Tracey O’Connor, E. Levine, Shipra Gandhi","doi":"10.53876/001c.90307","DOIUrl":"https://doi.org/10.53876/001c.90307","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"49 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138597775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Important Role of Cell Therapy in Multiple Myeloma: Three Reasons Why It’s Here to Stay","authors":"S. Sidana","doi":"10.53876/001c.89140","DOIUrl":"https://doi.org/10.53876/001c.89140","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139268369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The rates of AIDS-defining cancers have plummeted for people living with HIV (PLWH) and who have access to highly active antiretroviral therapies. In contrast, as survival of PLWH has improved and now rivals that of age-matched controls, rates of non-AIDS-defining cancers are increasing. Exposure to oncogenic viruses including human papillomavirus (HPV) as well as to traditional carcinogens, such as tobacco and alcohol are among the reasons for many of these cancers. Worldwide, anal cancer rates are increasing, and this is particularly true for high-grade squamous intraepithelial lesions (HSIL) evolving into invasive anal cancer in PLWH. Herein, I briefly review the oncogenic viruses most important in the pathogenesis of AIDS-defining and non-AIDS-defining malignancies and then focus on the link between HPV and anal cancer and efforts to minimize the risk of anal cancer in PLWH. The Anal Cancer/HSIL Outcomes Research (ANCHOR) study is a randomized phase III clinical trial which enrolled nearly 4500 participants across 25 diverse cities in the United States. PLWH who at time of enrollment were 35 years of age or older and who had biopsy-proven HSIL were eligible to take part in the study. The study is the first to show that screening and treating HSIL in a group at high risk for anal cancer can lead to a reduction in anal cancer incidence. Lessons learned from the ANCHOR study may also provide a blueprint for best practices when reaching out and recruiting marginalized groups with cancer into clinical trials. Much work is needed to plan for screening and treatment programs, including better algorithms for referral for high resolution anoscopy (HRA), and increased training to develop a workforce proficient in HRA screening and treatment of anal cancer. The development of progression biomarkers to identify those with HSIL most in need of treatment is essential. Finally, a more detailed analysis of costs and benefits of screen and treat algorithms for this malignancy is necessary for anal cancer screening to be implemented on a global scale.
{"title":"High Grade Anal Dysplasia in People Living with HIV: A Review of the Anal Cancer/HSIL Outcomes Research (ANCHOR) Trial. Implications for Screening and Treatment Strategies to Minimize Anal Cancer in a Very High-risk Population","authors":"D. Aboulafia","doi":"10.53876/001c.77452","DOIUrl":"https://doi.org/10.53876/001c.77452","url":null,"abstract":"The rates of AIDS-defining cancers have plummeted for people living with HIV (PLWH) and who have access to highly active antiretroviral therapies. In contrast, as survival of PLWH has improved and now rivals that of age-matched controls, rates of non-AIDS-defining cancers are increasing. Exposure to oncogenic viruses including human papillomavirus (HPV) as well as to traditional carcinogens, such as tobacco and alcohol are among the reasons for many of these cancers. Worldwide, anal cancer rates are increasing, and this is particularly true for high-grade squamous intraepithelial lesions (HSIL) evolving into invasive anal cancer in PLWH. Herein, I briefly review the oncogenic viruses most important in the pathogenesis of AIDS-defining and non-AIDS-defining malignancies and then focus on the link between HPV and anal cancer and efforts to minimize the risk of anal cancer in PLWH. The Anal Cancer/HSIL Outcomes Research (ANCHOR) study is a randomized phase III clinical trial which enrolled nearly 4500 participants across 25 diverse cities in the United States. PLWH who at time of enrollment were 35 years of age or older and who had biopsy-proven HSIL were eligible to take part in the study. The study is the first to show that screening and treating HSIL in a group at high risk for anal cancer can lead to a reduction in anal cancer incidence. Lessons learned from the ANCHOR study may also provide a blueprint for best practices when reaching out and recruiting marginalized groups with cancer into clinical trials. Much work is needed to plan for screening and treatment programs, including better algorithms for referral for high resolution anoscopy (HRA), and increased training to develop a workforce proficient in HRA screening and treatment of anal cancer. The development of progression biomarkers to identify those with HSIL most in need of treatment is essential. Finally, a more detailed analysis of costs and benefits of screen and treat algorithms for this malignancy is necessary for anal cancer screening to be implemented on a global scale.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122611676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kian C. Banks, E. T. Sumner, A. Alabaster, D. Hsu, Charles Quesenberry Jr, L. Sakoda, J. Velotta
In a cross-sectional analysis of adults diagnosed with lung cancer at ages ≥30 years from 2007-2018 within an integrated healthcare system, overall and sex-specific prevalence of never smoking were estimated according to sociodemographic and clinical characteristics. Adjusted prevalence ratio (aPR) and 95% confidence interval (CI) were also estimated using modified Poisson regression to identify patient characteristics associated with never smoking, overall and by sex. Similar analyses were conducted to explore whether prevalence and association patterns differed between non-Hispanic White and Asian/Pacific Islander patients.
{"title":"Sociodemographic characteristics associated with never smokers with lung cancer in an integrated health system","authors":"Kian C. Banks, E. T. Sumner, A. Alabaster, D. Hsu, Charles Quesenberry Jr, L. Sakoda, J. Velotta","doi":"10.53876/001c.73867","DOIUrl":"https://doi.org/10.53876/001c.73867","url":null,"abstract":"In a cross-sectional analysis of adults diagnosed with lung cancer at ages ≥30 years from 2007-2018 within an integrated healthcare system, overall and sex-specific prevalence of never smoking were estimated according to sociodemographic and clinical characteristics. Adjusted prevalence ratio (aPR) and 95% confidence interval (CI) were also estimated using modified Poisson regression to identify patient characteristics associated with never smoking, overall and by sex. Similar analyses were conducted to explore whether prevalence and association patterns differed between non-Hispanic White and Asian/Pacific Islander patients.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"128 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120948573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Maternal Health Care Advocacy: The Michigan Society of Hematology and Oncology (MSHO) and the Michigan Criminal Abortion Ban","authors":"J. Winegarden, Mary Kay Makarewicz","doi":"10.53876/001c.73877","DOIUrl":"https://doi.org/10.53876/001c.73877","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"86 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127655647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oral Anticancer Chemotherapy Parity- The Michigan Society of Hematology and Oncology (MSHO) Experience","authors":"Jerome E. Seid","doi":"10.53876/001c.73920","DOIUrl":"https://doi.org/10.53876/001c.73920","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134270124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：